Frank J. Sasinowski, M.S., M.P.H., J.D., has helped secure FDA approval for hundreds of new drugs; Frank was involved in 6 of the most recent 8 drugs FDA approved by way of its accelerated approval process. Frank is involved in many cell and gene therapies and aided significantly in the first approved systemic gene therapy, Zolgensma. Frank joined FDA in 1983 and in 1987, he left the FDA office and joined Hyman, Phelps & McNamara.
In 2000, Frank was elected to the Board of Directors of NORD, where he served until 2016. In 2017 Frank joined the Board of the Everylife Foundation for Rare Diseases. In May 2013, NORD awarded Frank its first ever Lifetime Achievement Award. In August 2018 Frank was appointed to the Board of Directors for the Alliance for Regenerative Medicine (ARM) Foundation for Cell and Gene Medicine. Frank is a founding Board member of the IndoUSrare patient organization and also a founding Board member of n-Lorem. Frank has also served on the Board of Directors of the United States Pharmacopeia (USP) and has
served on the board of several biotechnology companies.
Since 2014, Frank has been an Adjunct Professor of Neurology at the University of Rochester School of Medicine. Frank testified at the May 2014 inaugural congressional hearing on the 21st Century Cures law. In 2012, President Obama recognized Frank’s contributions to the President’s Council of Advisors on Science and Technology (PCAST) report.
